CEO Braidstent (The Collider Programme)

BRAIDSTENT | Biodegradable Ureteral Stent

CEO & Co-Founder Opportunity | MedTech | Urology | Implantable Devices

Are you ready to build a high-impact MedTech spin-off addressing one of the most painful and unresolved problems in urology?

BraidStent is an innovative biodegradable ureteral stent designed to eliminate the major complications associated with current stents. The project is supported by a strong preclinical process and is currently at TRL 5, with in vivo proof of concept already achieved.

We are looking for an entrepreneurial CEO to lead the spin-off creation and drive regulatory, industrial and commercial strategy

About BraidStent

Ureteral stents are associated with high morbidity and complications, affecting up to 80% of patients with ureteral stones. Main limitations of current solutions includes: Bladder and lumbar pain, urinary infections, encrustation, forgotten stent syndrome, need for a second intervention for removal, high psychological burden

BraidStent is a biodegradable, anti-reflux intraureteral stent designed to eliminate the root causes of patient discomfort:

• Anti-reflux / intraureteral design, avoiding trigone irritation and ureterovesical junction crossing
• Biodegradable polymers/copolymers, enabling predictable hydrolytic degradation and natural urinary elimination
• No need for surgical removal
• Reduced complications in pediatric patients (no anesthesia required for removal)
• Potential for controlled drug delivery as a scaffold

Why BraidStent

• TRL 5 with in vivo proof of concept
• Preclinical validation already published in peer-reviewed journals
• Clear clinical unmet need with strong patient impact
• Cost reduction for healthcare systems (no second intervention required)
• Disruptive positioning versus existing market devices (Boston Scientific, Teleflex, etc.)
• Roadmap defined toward industrialization, clinical trials and market access (2027–2032)
• Key opinion leader as a Principal Investigator and Founder Dr. Federico Soria, and backed by IRICYS.

Your Role as CEO & Co-Founder (Next 6 Months)

You will lead BraidStent through a critical transition phase:

• Spin-off creation and alignment with the Technology Transfer Office
• Definition of regulatory pathway (CE/MDR strategy)
• New patent application and IP strategy refinement
• Structuring preclinical development and preparation for clinical validation
• Designing industrialization strategy and manufacturing roadmap
• Leading fundraising efforts (public & private)
• Establishing strategic partnerships (manufacturers, clinical centers, distributors)

The Offer

• Relevant equity as CEO & Co-Founder upon company incorporation.
• €6,000 stipend during validation phase (3 monthly instalments of €2,000)
• Opportunity to access a participative loan of up to €50,000 to finance early-stage activities.
• Access to The Collider venture-building programme, including: Hands on support in regulatory, IP, clinical strategy and fundraising, market validation, team formation, shareholder structuring and spin-off creation
• International exposure through The Collider ecosystem (4YFN, Mobile World Congress, corporate & investor networks)
• Coworking space in Barcelona (Tech Barcelona – Pier 01)
• Venture-builder support for two years post-incorporation, including in-kind services, community access and portfolio perks.

This Opportunity Is for You If

• You are an entrepreneur with experience in MedTech, medical devices or healthcare innovation
• Previous experience as founder or co-founder
• Familiar with CE/MDR regulatory processes and clinical validation pathways
• Experience in fundraising and strategic partnerships
• Comfortable operating in hospital-driven B2B sales environments
• Able to bridge clinical needs, engineering development and business strategy
• Eligible to work in Spain (passport or valid visa required)
• Fluent in Spanish and English